
<![CDATA[Fruzaqla and Tyvyt Combo Shows Improved Outcomes in Advanced Kidney Cancer ]]>
Patients with advanced renal cell carcinoma whose disease has progressed on first-line therapies may benefit from the combination of Fruzaqla (fruquintinib) and Tyvyt (sintilimab), according to data from the FRUSICA-2 registration trial, which were shared …